Castle Biosciences Inc
$ 33.15
3.92%
13 Feb - close price
- Market Cap 931,118,000 USD
- Current Price $ 33.15
- High / Low $ 33.66 / 31.84
- Stock P/E N/A
- Book Value 16.02
- EPS -0.43
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.03 %
- 52 Week High 44.28
- 52 Week Low 14.59
About
Castle Biosciences Inc. is a commercial-stage diagnostics company dedicated to improving the quality of life for patients with skin cancer and other diseases through innovative, gene-expression profiling tests. The company's flagship product, DecisionDx®-Melanoma, aids in risk stratification and treatment decision-making for patients with melanoma by evaluating gene expression levels. Committed to advancing precision medicine, Castle Biosciences leverages its proprietary platform to develop additional assays that enhance clinical outcomes. With a strong focus on research and development, the company is well-positioned to expand its product portfolio and address unmet needs in oncology, thereby driving long-term growth and shareholder value.
Analyst Target Price
$48.57
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-08-04 | 2025-04-30 | 2025-02-26 | 2024-11-04 | 2024-08-05 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-02 | 2023-05-03 | 2023-02-28 |
| Reported EPS | -0.02 | 0.15 | -0.9035 | 0.32 | 0.08 | 0.31 | -0.09 | -0.1 | -0.26 | -0.7 | -1.1 | -0.78 |
| Estimated EPS | -0.52 | -0.51 | -0.0657 | 0.04 | -0.06 | -0.27 | -0.33 | -0.54 | -0.76 | -0.91 | -0.89 | -0.84 |
| Surprise | 0.5 | 0.66 | -0.8378 | 0.28 | 0.14 | 0.58 | 0.24 | 0.44 | 0.5 | 0.21 | -0.21 | 0.06 |
| Surprise Percentage | 96.1538% | 129.4118% | -1275.1903% | 700% | 233.3333% | 214.8148% | 72.7273% | 81.4815% | 65.7895% | 23.0769% | -23.5955% | 7.1429% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CSTL
2026-02-11 13:58:22
Castle Biosciences (CSTL) shares surged after the FDA granted Breakthrough Device designation to its investigational prognostic test for cutaneous squamous cell carcinoma (cSCC). This designation is expected to accelerate the review process for the test, which aims to identify high-risk cSCC patients. The news led to a significant increase in the company's stock value during intraday trading.
2026-02-09 09:35:00
Castle Biosciences (CSTL) shares have recently dropped by 16.8% but may be poised for a trend reversal. Technical indicators like the Relative Strength Index (RSI) show the stock is oversold, while fundamental analysis highlights strong upward revisions in earnings estimates by Wall Street analysts. Additionally, CSTL holds a Zacks Rank #1 (Strong Buy), suggesting a potential near-term turnaround.
2026-02-09 09:35:00
Castle Biosciences (CSTL) has experienced a 16.8% drop in stock value over the past four weeks, but indicators suggest a potential trend reversal. Its Relative Strength Index (RSI) is at an oversold level of 25.01, and analysts have increased earnings estimates for the current year, leading to a 13.5% rise in the consensus EPS estimate. Furthermore, CSTL holds a Zacks Rank #1 (Strong Buy), pointing towards a near-term turnaround.
2026-02-08 08:59:17
Allianz Asset Management GmbH reduced its stake in Castle Biosciences (NASDAQ:CSTL) by 9.2% in the third quarter, now holding 648,351 shares valued at $14.8 million. Despite this, institutional investors collectively own 92.60% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $47.14. Company insiders have been net sellers, disposing of 39,425 shares worth approximately $1.54 million in the last quarter.
2026-02-06 00:56:13
Castle Biosciences (NASDAQ:CSTL) insider Derek Maetzold sold 3,200 shares of the company's stock on February 3rd for a total of $127,712, reducing his stake by 3.65%. Following the transaction, Maetzold directly owns 84,515 shares. The stock traded down $2.56 to $32.40 on heavy volume, while institutional investors own 92.6% and analysts maintain a "Moderate Buy" rating with an average price target of $47.14.
2026-02-06 00:55:13
Derek Maetzold, an insider at Castle Biosciences (NASDAQ:CSTL), recently sold 817 shares of the company's stock for approximately $31,038, reducing his total holdings by 0.97%. The sale occurred on February 4th, with shares trading down afterward on heavy volume. Despite the insider selling, Castle Biosciences reported an EPS beat for its last quarter and receives a consensus "Moderate Buy" rating from analysts with an average target price of $47.14.
